Abstract 273P
Background
We compared the diagnostic performance of cognitive transrectal MRI-targeted biopsy (MRITB) between three anatomical zones of the prostate.
Methods
Of the 569 initial cases with suspected prostate cancer, those who received standard biopsy (14-region, 18-core biopsy: SB) between June 2019 and March 2023 were selected (SB 57 cases, SB+MRITB 509 cases). SB alone was performed in PI-RADS v2.1 ≦2, and MRITB was added in ≧3. In this study, we investigated whether zonal anatomy affects the diagnostic performance of MRITB retrospectively.
Results
In 569 cases, 394 cases (69.2%) were positive for cancer. Of 394 cancer cases, 25 (6.3%) were from SB alone and 369 (93.7%) from SB+MRITB. According to the Epstein criteria, 359 cases (91.1%) were clinically significant. In all cases, the diagnostic performance of MRITB was 80.1% for sensitivity, 20.5% for specificity, 71.4% for positive predictive value, 29.4% for negative predictive value, and 63.0% for accuracy. The true positive rates of cancer detection by MRITB in each zone were 22 cores (43.1%) in CZ, 125 cores (41.9%) in TZ, and 283 cores (64.6%) in PZ. CZ and TZ groups were significantly lower than the PZ group, respectively, and especially, midgland TZ was the highest false-positive rates compared to midgland-apex TZ (87.3% v.s.33.3%).
Conclusions
In the case of SB including apex anterior biopsy, MRITB alone missed clinically significant cancers in 65 cases (18.1%) in PI-RADS v2.1 ≥3, which was a higher rate than those reported by many previous reports. In contrast, MRITB showed a high false-positive rate especially in TZ, suggesting that the positive criteria and approach model for these lesions need to be discussed.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Y. Toyama.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
153P - IMbrave150: Exploratory analyses for investigating associations between overall survival (OS) and depth of response (DpR) or duration of response (DoR) in patients (pts) with unresectable hepatocellular carcinoma (HCC)
Presenter: Masatoshi Kudo
Session: Poster Display
Resources:
Abstract
154P - Adverse events (AEs) as potential predictive factors of activity in patients with advanced hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab (AB)
Presenter: Mara Persano
Session: Poster Display
Resources:
Abstract
155P - Penpulimab combined with anlotinib and nab-paclitaxel plus gemcitabine (PAAG) as first-line treatment for advanced metastatic pancreatic cancer: A prospective, multicenter, single-arm, phase II study
Presenter: Juan Du
Session: Poster Display
Resources:
Abstract
156P - Phase II trial of second-line regorafenib in patients with unresectable hepatocellular carcinoma after progression on first-line atezolizumab plus bevacizumab: REGONEXT trial
Presenter: Jaekyung Cheon
Session: Poster Display
Resources:
Abstract
157P - T/N ratio and radiation dose delivered do not correlate with the development of Radioembolization-Induced Liver Disease (REILD) in Hepatocellular Carcinoma (HCC) following Y90 selective internal radiation therapy (Y90-SIRT): A retrospective, single tertiary centre cohort study
Presenter: Daniel Yang Yao Peh
Session: Poster Display
Resources:
Abstract
158P - Single-cell RNA sequencing via Endoscopic Ultrasoundguided Fine-Needle Biopsy (EUS-FNB) Pancreatic Biopsies uncovered an aggressive subclone with a poor prognosis
Presenter: Yung-yeh Su
Session: Poster Display
Resources:
Abstract
159P - Classical computer vision and modern deep-learning of pancreatic stroma histology features to diagnose cancer
Presenter: Abdelhakim Khellaf
Session: Poster Display
Resources:
Abstract
160P - Interim analysis of the NAPOLEON-2 study: Safety evaluation of nano-liposomal irinotecan with fluorouracil and folinic acid for advanced pancreatic cancer
Presenter: Wataru Kusano
Session: Poster Display
Resources:
Abstract
161P - Screening and COnsensus based on Practices and Evidence (SCOPE): Real-world survey on Japanese and rest-of-world practice patterns in resectable pancreatic cancer
Presenter: Elizabeth Smyth
Session: Poster Display
Resources:
Abstract
162P - Recurrence pattern of hepatocellular carcinoma patients receiving curative surgery of RFA: An update
Presenter: Long Chan
Session: Poster Display
Resources:
Abstract